Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Return to: PBR Home | Drug Research
Today in Drug Research

Drug Research

Eisai and Halozyme to evaluate combination drug for treatment of metastatic breast cancer Eisai and Halozyme Therapeutics have agreed to evaluate the combination of their drugs, Halaven (eribulin) and PEGPH20 (PEGylated recombinant human hyaluronidase), respectively, in the treatment of first line HER2-negative metastatic breast cancer. Drug Research > Drug Discovery & Development > News

Latest Drug Research News by Sector

Select a sector from the list or browse by sector below:

Drug Delivery

Corium gets US patent for MicroCor transdermal system
By PBR Staff Writer
The US Patent and Trademark Office issued US Patent No. 9,114,238, related to Corium International's new MicroCor transdermal system.
Drug Research > Drug Delivery > News
Alvogen to buy four pharmaceutical products from Pfizer for US market
By PBR Staff Writer
Alvogen has entered into a definitive agreement to acquire a portfolio of four pharmaceutical products from Pfizer for marketing in the US.
Drug Research > Drug Delivery > News

Drug Discovery & Development

Soligenix gets additional NIAID funding to advance development of OrbeShield in GI ARS
Soligenix (SNGX), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP).
Drug Research > Drug Discovery & Development > News
Symic Biomedical gets $1.5m NIH Phase II SBIR grant to develop proteoglycan mimetic therapeutics
Platform therapeutic company Symic Biomedical (Symic) announced that it has received a $1.5m Phase II SBIR grant from the National Institutes of Health (NIH) to further develop its therapeutic agent to reduce arteriovenous fistula (AVF) failures, a significant unmet clinical need in end stage renal disease (ESRD) patients undergoing hemodialysis.
Drug Research > Drug Discovery & Development > News